Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability
Kyung-Ok Kim1, Woo-Jae Park2,3, YunJae Jung3,4
1Gachon Medical Research Institute, Gil Medical Center, Gachon University, Incheon, Korea.
Abstract:
We analyzed responsiveness of KRAS-mutated CRC cell lines with distinctive MSI status against mitogen-activated protein kinase (MEK) inhibitor (selumetinib; AZD) and/or B-raf proto-oncogene (BRAF) kinase inhibitor (vemurafenib; PLX). The viability of MSI-high (MSI-H) KRAS-mutated LS174T cells treated with AZD or PLX was 24.5 ± 0.9% or 71.4 ± 3.6%, respectively, and the viability of microsatellite stable (MSS) KRAS-mutated SW480 cells for AZD or PLX was 57.4 ± 3.1% or 43.1 ± 1.8%, respectively. These observations imply that the therapeutic efficacy of MEK kinase inhibitors or BRAF kinase inhibitors against KRAS-mutated colon cancer cells may differ between MSI-H and MSS. However, a combination of both inhibitors synergistically inhibits the proliferation of KRAS-mutated colon cancer cells regardless of MSI status. The underlying synergistic cytotoxic efficacy of AZD/PLX combination on KRAS-mutated colon cancer cells with different MSI status was further substantiated by markedly decreased phosphorylation of ERK in both LS74T and SW480 cell lines upon AZD and PLX treatment. Based on these collective data, we propose that MSI status should be considered when MEK kinase inhibitor or BRAF kinase inhibitor is treated for KRAS-mutated colon cancer, and that combination of both inhibitors synergistically inhibit proliferation of KRAS-mutated colon cancer cells independent of MSI status.
Insights
Microsatellite instability (MSI) status impacts MEK or BRAF inhibitor effectiveness in KRAS-mutated colon cancer. Combination therapy shows synergistic effects, inhibiting proliferation regardless of MSI status.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- KRAS-mutated colorectal cancer (CRC) presents therapeutic challenges.
- Distinct microsatellite instability (MSI) statuses (MSI-high/MSI-H and microsatellite stable/MSS) influence treatment response.
- Targeting MEK and BRAF pathways is a strategy for CRC treatment.
Purpose of the Study:
- To investigate the differential responsiveness of KRAS-mutated CRC cell lines with varying MSI statuses to MEK and BRAF inhibitors.
- To evaluate the synergistic potential of combining MEK and BRAF inhibitors in KRAS-mutated CRC.
- To determine if MSI status affects the efficacy of single-agent or combination therapy.
Main Methods:
- Utilized KRAS-mutated CRC cell lines with distinct MSI statuses (LS174T - MSI-H, SW480 - MSS).
- Assessed cell viability upon treatment with MEK inhibitor (selumetinib; AZD) and/or BRAF inhibitor (vemurafenib; PLX).
- Measured extracellular signal-regulated kinase (ERK) phosphorylation to confirm pathway inhibition.
Main Results:
- MSI-H KRAS-mutated cells showed higher sensitivity to MEK inhibition (AZD) compared to BRAF inhibition (PLX).
- MSS KRAS-mutated cells exhibited greater sensitivity to BRAF inhibition (PLX) than MEK inhibition (AZD).
- Combination therapy (AZD/PLX) synergistically inhibited proliferation in both MSI-H and MSS KRAS-mutated cells, evidenced by reduced ERK phosphorylation.
Conclusions:
- MSI status is a critical factor influencing the efficacy of individual MEK or BRAF inhibitors in KRAS-mutated CRC.
- Combined MEK and BRAF inhibition offers a synergistic therapeutic strategy for KRAS-mutated CRC, irrespective of MSI status.
- Consideration of MSI status is recommended for personalized treatment selection with MEK/BRAF inhibitors in KRAS-mutated CRC.
More Related Videos
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
MAPK Signaling Cascades
The Ras Gene
Ras is a...
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
